bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Fig 8 from Ubiquitin Ligases Siah1a/2 Control Alveolar Macrophage Functions to Limit Carcinogen-Induced Lung Adenocarcinoma
Authors: Scortegagna Marzia , Du Yuanning , Bradley Linda M. , Wang Kun , Molinolo Alfredo , Ruppin Eytan , Murad Rabi , Ronai Ze'ev A.
Published: June 2023

Supp Fig 8
Figure 2 from Shortwave Infrared Imaging Enables High-Contrast Fluorescence-Guided Surgery in Neuroblastoma
Authors: Privitera Laura , Waterhouse Dale J. , Preziosi Alessandra , Paraboschi Irene , Ogunlade Olumide , Da Pieve Chiara , Barisa Marta , Ogunbiyi Olumide , Weitsman Gregory , Hutchinson J. Ciaran , Cross Kate , Biassoni Lorenzo , Stoyanov Danail , Sebire Neil , Beard Paul , De Coppi Paolo , Kramer-Marek Gabriela , Anderson John , Giuliani Stefano
Published: June 2023

Overview of the in vivo preclinical study. A, Six to 8-week-old athymic nude female mice LAN-1 xenografts were injected with either anti–GD2-IR800 or anti–GD-IR12. The control mice were not injected. Mice were imaged at 24, 48, 72, and 96 hours using the IVIS Spectrum and the multispectral NIR-I/SWIR fluorescence imaging system. B, At each end time point, mice were euthanized and imaged using the IVIS (n = 3) and the multispectral NIR-I/SWIR fluorescence imaging system (n = 1). The unexposed tumors were imaged, followed by the exposed tumors and the excised organs of interest.
Supplementary Fig 6 from Ubiquitin Ligases Siah1a/2 Control Alveolar Macrophage Functions to Limit Carcinogen-Induced Lung Adenocarcinoma
Authors: Scortegagna Marzia , Du Yuanning , Bradley Linda M. , Wang Kun , Molinolo Alfredo , Ruppin Eytan , Murad Rabi , Ronai Ze'ev A.
Published: June 2023

Sup Fig 6
Supplementary Fig 5 from Ubiquitin Ligases Siah1a/2 Control Alveolar Macrophage Functions to Limit Carcinogen-Induced Lung Adenocarcinoma
Authors: Scortegagna Marzia , Du Yuanning , Bradley Linda M. , Wang Kun , Molinolo Alfredo , Ruppin Eytan , Murad Rabi , Ronai Ze'ev A.
Published: June 2023

Sup Fig 5
Supplementary Fig 3 from Ubiquitin Ligases Siah1a/2 Control Alveolar Macrophage Functions to Limit Carcinogen-Induced Lung Adenocarcinoma
Authors: Scortegagna Marzia , Du Yuanning , Bradley Linda M. , Wang Kun , Molinolo Alfredo , Ruppin Eytan , Murad Rabi , Ronai Ze'ev A.
Published: June 2023

Sup Fig 3
Supplementary Figure S1-9 from An In Vivo CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression
Authors: Lu Xun-Xi , Yang Wen-Xiao , Pei Yu-Chen , Luo Hong , Li Xiao-Guang , Wang Yun-Jin , Zhang Guo-Liang , Ling Hong , Shao Zhi-Ming , Hu Xin
Published: June 2023

Fig. S1. CRISPR/Cas9 library quality examination.Fig. S2. SNRPC is upregulated and associated with poor prognosis in TNBC.Fig. S3. SNRPC promotes cell proliferation and migration in vitro.Fig. S4. The zinc finger of SNRPC is highly conserved among kinds of species.Fig. S5. SNRPC maintains the stability of U1 snRNP.Fig. S6. SNRPC is involved in tumor-related pathways.Fig. S7. SNRPC participates in the RNA Pol II activity.Fig. S8. SNRPC is positively correlated with TNFAIP2, E2F2 and CDK4.Fig. S9. SNRPC mediates TNBC progression partially via the TNFAIP2-Rac1-β-catenin axis.
Supplementary Text from CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations
Authors: Reinhold William C. , Wilson Kelli , Elloumi Fathi , Bradwell Katie R. , Ceribelli Michele , Varma Sudhir , Wang Yanghsin , Duveau Damien , Menon Nikhil , Trepel Jane , Zhang Xiaohu , Klumpp-Thomas Carleen , Micheal Samuel , Shinn Paul , Luna Augustin , Thomas Craig , Pommier Yves
Published: June 2023

Source data
Table S2 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases
Authors: Jailkhani Noor , Clauser Karl R. , Mak Howard H. , Rickelt Steffen , Tian Chenxi , Whittaker Charles A. , Tanabe Kenneth K. , Purdy Stephen R. , Carr Steven A. , Hynes Richard O.
Published: June 2023

Supplementary Table S2
Supplementary Table 5 from CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations
Authors: Reinhold William C. , Wilson Kelli , Elloumi Fathi , Bradwell Katie R. , Ceribelli Michele , Varma Sudhir , Wang Yanghsin , Duveau Damien , Menon Nikhil , Trepel Jane , Zhang Xiaohu , Klumpp-Thomas Carleen , Micheal Samuel , Shinn Paul , Luna Augustin , Thomas Craig , Pommier Yves
Published: June 2023

Multivariate prediction
Table S1 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases
Authors: Jailkhani Noor , Clauser Karl R. , Mak Howard H. , Rickelt Steffen , Tian Chenxi , Whittaker Charles A. , Tanabe Kenneth K. , Purdy Stephen R. , Carr Steven A. , Hynes Richard O.
Published: June 2023

Supplementary Table S1
Supplementary Table 4 from CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations
Authors: Reinhold William C. , Wilson Kelli , Elloumi Fathi , Bradwell Katie R. , Ceribelli Michele , Varma Sudhir , Wang Yanghsin , Duveau Damien , Menon Nikhil , Trepel Jane , Zhang Xiaohu , Klumpp-Thomas Carleen , Micheal Samuel , Shinn Paul , Luna Augustin , Thomas Craig , Pommier Yves
Published: June 2023

Molecular targets
Supplementary Table 3 from CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations
Authors: Reinhold William C. , Wilson Kelli , Elloumi Fathi , Bradwell Katie R. , Ceribelli Michele , Varma Sudhir , Wang Yanghsin , Duveau Damien , Menon Nikhil , Trepel Jane , Zhang Xiaohu , Klumpp-Thomas Carleen , Micheal Samuel , Shinn Paul , Luna Augustin , Thomas Craig , Pommier Yves
Published: June 2023

Unique cell lines
Figure 6 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases
Authors: Jailkhani Noor , Clauser Karl R. , Mak Howard H. , Rickelt Steffen , Tian Chenxi , Whittaker Charles A. , Tanabe Kenneth K. , Purdy Stephen R. , Carr Steven A. , Hynes Richard O.
Published: June 2023

NJT6 detects tumors and lung metastases in vivo by immuno-PET/CT imaging with a high signal-to-noise ratio and low background. A, LM2 cells were injected in the MFP or via the tail vein of NSG mice to induce primary tumors or pulmonary metastases, respectively. Three weeks after tumor initiation, control and tumor-bearing mice were imaged with 64Cu-NJT6 immuno-PET/CT (top) or 18F-FDG PET/CT (bottom), Representative immuno-PET/CT images of maximum-intensity projections of mice imaged at 2 hours post-injection are shown. (i) NSG control mice; signals detected in kidney (K), liver (L), and bladder (B). (ii) Mouse bearing primary tumor; strong signals also detected in primary tumor (T). (iii) Mouse bearing pulmonary metastases; strong signals also detected in lung metastases (LM). (iv) Mouse bearing primary tumor imaged 24 hours after injection with labeled nanobodies; signals still detected in primary tumor. (v) Mouse bearing pulmonary metastases imaged 24 hours post-injection; signals still detected in lung metastases. (vi–viii) Representative images of control mice, mice with primary tumors, and mice with pulmonary metastases imaged with 18F-FDG PET/CT. H, heart. Images are representative of 6 to 7 mice with similar results. B,Ex vivo biodistribution of 64Cu-NJT6, expressed as %ID/g in various organs. N = 3 for all groups. C, Inset, data in B expressed as tissue-to-blood ratios for tumors/MFPs and lungs.
Figure 5 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases
Authors: Jailkhani Noor , Clauser Karl R. , Mak Howard H. , Rickelt Steffen , Tian Chenxi , Whittaker Charles A. , Tanabe Kenneth K. , Purdy Stephen R. , Carr Steven A. , Hynes Richard O.
Published: June 2023

Anti-TNC nanobodies recognize the ECM of primary tumors and lung metastases in a TNBC model. α-TNC nanobodies detect the ECM of tumors and lung metastases derived from LM2 TNBC cells. A and B, NSG mice bearing orthotopic tumors (A) or lung metastases (B) derived from LM2-TGL-ZsGreen cells were injected intravenously with Alexa-647 labeled nanobodies. Two hours after injection, indicated organs were resected and imaged by two-photon microscopy. Representative images are shown as an overlay of different channels. α -TNC nanobodies bound to the ECM of both primary tumors and lung metastases (arrowheads) but not normal tissue ECM (N). Scale bars, 100 μm.
Supplementary Table 1 from CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations
Authors: Reinhold William C. , Wilson Kelli , Elloumi Fathi , Bradwell Katie R. , Ceribelli Michele , Varma Sudhir , Wang Yanghsin , Duveau Damien , Menon Nikhil , Trepel Jane , Zhang Xiaohu , Klumpp-Thomas Carleen , Micheal Samuel , Shinn Paul , Luna Augustin , Thomas Craig , Pommier Yves
Published: June 2023

Unique non-cancer drugs
Figure 4 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases
Authors: Jailkhani Noor , Clauser Karl R. , Mak Howard H. , Rickelt Steffen , Tian Chenxi , Whittaker Charles A. , Tanabe Kenneth K. , Purdy Stephen R. , Carr Steven A. , Hynes Richard O.
Published: June 2023

TNC-specific nanobodies recognize human TNC with subnanomolar affinity. A, Clustal W–based sequence alignment of anti-human TNC nanobodies NJT3, NJT4, and NJT6. CDR, complementarity-determining region. B, Immunoblot showing specificity of TNC-specific nanobodies to human TNC protein. The nanobodies do not recognize mouse TNC in supernatants from TNC-overexpressing (OE) cell lines, supernatant from control cells (control sup), or human TNW. C, Anti-TNC nanobodies recognize human TNC in IHC on tissue sections of lung metastases derived from human TNBC cell line LM2. They did not recognize mouse TNC on tissue sections of lung metastases derived from murine TNBC cell line 4T1. The control rabbit monoclonal α-TNC antibody recognizes both human and mouse TNC. D, Dissociation constants (KD) of α -TNC nanobodies to immobilized human TNC protein measured using BLI. KD, ka, and kd values are listed. Black curves, original data; red curves, curve fitting. H&E, hematoxylin and eosin.
Supplemental Figure 2 from CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations
Authors: Reinhold William C. , Wilson Kelli , Elloumi Fathi , Bradwell Katie R. , Ceribelli Michele , Varma Sudhir , Wang Yanghsin , Duveau Damien , Menon Nikhil , Trepel Jane , Zhang Xiaohu , Klumpp-Thomas Carleen , Micheal Samuel , Shinn Paul , Luna Augustin , Thomas Craig , Pommier Yves
Published: June 2023

BRAF versus dabrafenib
Figure 1 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases
Authors: Jailkhani Noor , Clauser Karl R. , Mak Howard H. , Rickelt Steffen , Tian Chenxi , Whittaker Charles A. , Tanabe Kenneth K. , Purdy Stephen R. , Carr Steven A. , Hynes Richard O.
Published: June 2023

Schematic of ECM enrichment and proteomic analysis of patient metastasis samples for matrisome nanobody library construction and panning. A, Patient metastasis samples used for ECM enrichment and proteomics for identification of ECM proteins/signatures associated with patient metastases. CRC, colorectal cancer. B, Immunoblots showing sequential extraction steps (1–5; see Materials and Methods) to obtain the final insoluble ECM-enriched pellet. C, Simplified schematic of nanobody library construction and isolation of nanobodies against ECM proteins identified from proteomics signatures. (See also Supplementary Fig. S1 for details on immunogen and immunization schedule.) D, Simplified schematic of LC-MS/MS–based proteomics pipeline to characterize the matrisome of the human metastases.
Supplementary Table 1 from Chi3l1 Is a Modulator of Glioma Stem Cell States and a Therapeutic Target in Glioblastoma
Authors: Guetta-Terrier Charlotte , Karambizi David , Akosman Bedia , Zepecki John P. , Chen Jia-Shu , Kamle Suchitra , Fajardo J. Eduardo , Fiser Andras , Singh Ritambhara , Toms Steven A. , Lee Chun Geun , Elias Jack A. , Tapinos Nikos
Published: June 2023

Supplementary Table 1
Supplementary Figures from Chi3l1 Is a Modulator of Glioma Stem Cell States and a Therapeutic Target in Glioblastoma
Authors: Guetta-Terrier Charlotte , Karambizi David , Akosman Bedia , Zepecki John P. , Chen Jia-Shu , Kamle Suchitra , Fajardo J. Eduardo , Fiser Andras , Singh Ritambhara , Toms Steven A. , Lee Chun Geun , Elias Jack A. , Tapinos Nikos
Published: June 2023

Supplementary Figures and Legends
Supplementary Material from Prospective Analysis Reveals Associations between Carbohydrate Intakes, Genetic Predictors of Short-Chain Fatty Acid Synthesis, and Colorectal Cancer Risk
Authors: Watling Cody Z. , Kelly Rebecca K. , Murphy Neil , Gunter Marc , Piernas Carmen , Bradbury Kathryn E. , Schmidt Julie A. , Key Timothy J. , Perez-Cornago Aurora
Published: June 2023

Supplementary Material
Figure 3 from Prospective Analysis Reveals Associations between Carbohydrate Intakes, Genetic Predictors of Short-Chain Fatty Acid Synthesis, and Colorectal Cancer Risk
Authors: Watling Cody Z. , Kelly Rebecca K. , Murphy Neil , Gunter Marc , Piernas Carmen , Bradbury Kathryn E. , Schmidt Julie A. , Key Timothy J. , Perez-Cornago Aurora
Published: June 2023

Multivariable-adjusted hazard ratios (95% CI) for intake of carbohydrates and fiber and colorectal cancer risk separated by genetically predicted host short-chain fatty acid production for butyrate (A) and propionate (n = 87,417; B). All models are stratified by sex, age at recruitment, adjusted for region of recruitment, first 10 genetic principal components, body mass index, height, physical activity, Townsend deprivation index, education, smoking, alcohol consumption, diabetes status, nonsteroidal anti-inflammatory drug use, red and processed meat intake, fruit and vegetable intake (except when fiber from vegetables and/or fruits, and non-free sugar intake was the exposure), energy intake, and female-specific covariates: menopausal hormone therapy use and menopausal status. Analyses are restricted to white British participants. χ2 and P value represents improvement of fit obtained from likelihood ratio tests for including an interaction term between butyrate or propionate polygenic score and carbohydrate type/source (modeled as a 5% energy increment) or fiber source (modeled as a 5 gram/day increment) into the model.
Figure S3 from Distinct Nrf2 Signaling Thresholds Mediate Lung Tumor Initiation and Progression
Authors: DeBlasi Janine M. , Falzone Aimee , Caldwell Samantha , Prieto-Farigua Nicolas , Prigge Justin R. , Schmidt Edward E. , Chio Iok In Christine , Karreth Florian A. , DeNicola Gina M.
Published: June 2023

Supplementary Fig. S3 shows analysis of lung tumor burden and tumor cell proliferation/death in the Kras; p53 model with Keap1/Nrf2 mutation.
Supplementary Data from ZDHHC2-Mediated AGK Palmitoylation Activates AKT–mTOR Signaling to Reduce Sunitinib Sensitivity in Renal Cell Carcinoma
Authors: Sun Yan , Zhu Liang , Liu Pian , Zhang Huan , Guo Feng , Jin Xin
Published: June 2023

Supplementary Data
Figure S1 from Distinct Nrf2 Signaling Thresholds Mediate Lung Tumor Initiation and Progression
Authors: DeBlasi Janine M. , Falzone Aimee , Caldwell Samantha , Prieto-Farigua Nicolas , Prigge Justin R. , Schmidt Edward E. , Chio Iok In Christine , Karreth Florian A. , DeNicola Gina M.
Published: June 2023

Supplementary Fig. S1 shows that the CA-Keap1R554Q allele does not exhibit hypomorphism in mouse embryonic fibroblasts.
Supplementary Tables 1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Authors: Lin Yansong , Qin Shukui , Yang Hui , Shi Feng , Yang Aimin , Han Xingmin , Liu Bin , Li Zhiyong , Ji Qinghai , Tang Lijun , Deng Zhiyong , Ding Yong , Fu Wei , Xie Xianhe , Li Linfa , He Xiaohui , Lv Zhongwei , Ma Qingjie , Shen Zan , Guo Zhuming , Chen Zhendong , Cui Yali , Tan Jian , Gao Zairong , Jing Shanghua , Lu Keyi , Luo Xianyang , Zhang Yuan , Fang Yong , Li Zhendong , Cheng Yizhuang , Lei Shangtong , Luan Sha , Chen Guang , Wang Guihua , Wu Liqing , Liu Lingling
Published: June 2023

Supplementary Tables
Supplementary Table S4 from Genomic Profiling of Radiation-Induced Sarcomas Reveals the Immunologic Characteristics and Its Response to Immune Checkpoint Blockade
Authors: Hong Dong-Chun , Yang Jing , Sun Cong , Liu Yuan-Tao , Shen Lu-Jun , Xu Bu-Shu , Que Yi , Xia Xiaojun , Zhang Xing
Published: June 2023

Treatment-related adverse events of 30 RIS patients treated with chemotherapy plus anti-PD-1 antibody.
Figure S1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Authors: Lin Yansong , Qin Shukui , Yang Hui , Shi Feng , Yang Aimin , Han Xingmin , Liu Bin , Li Zhiyong , Ji Qinghai , Tang Lijun , Deng Zhiyong , Ding Yong , Fu Wei , Xie Xianhe , Li Linfa , He Xiaohui , Lv Zhongwei , Ma Qingjie , Shen Zan , Guo Zhuming , Chen Zhendong , Cui Yali , Tan Jian , Gao Zairong , Jing Shanghua , Lu Keyi , Luo Xianyang , Zhang Yuan , Fang Yong , Li Zhendong , Cheng Yizhuang , Lei Shangtong , Luan Sha , Chen Guang , Wang Guihua , Wu Liqing , Liu Lingling
Published: June 2023

Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.
Supplementary Table S3 from Genomic Profiling of Radiation-Induced Sarcomas Reveals the Immunologic Characteristics and Its Response to Immune Checkpoint Blockade
Authors: Hong Dong-Chun , Yang Jing , Sun Cong , Liu Yuan-Tao , Shen Lu-Jun , Xu Bu-Shu , Que Yi , Xia Xiaojun , Zhang Xing
Published: June 2023

Clinical characteristics of patients treated with chemotherapy alone and chemotherapy plus anti-PD-1 antibody in RIS group.
Supplementary Table S1 from Integrative Single-Cell and Bulk Transcriptomes Analyses Identify Intrinsic HNSCC Subtypes with Distinct Prognoses and Therapeutic Vulnerabilities
Authors: Dai Yibin , Wang Ziyu , Xia Yingchao , Li Jin , Wu Yaping , Wang Yanling , Jiang Hongbing , Cheng Jie
Published: June 2023

Detailed proportions of cells in 5 scRNA-seq datasets
Supplementary Figure S3 from Genomic Profiling of Radiation-Induced Sarcomas Reveals the Immunologic Characteristics and Its Response to Immune Checkpoint Blockade
Authors: Hong Dong-Chun , Yang Jing , Sun Cong , Liu Yuan-Tao , Shen Lu-Jun , Xu Bu-Shu , Que Yi , Xia Xiaojun , Zhang Xing
Published: June 2023

Comparison between RIS group and SARC group in mRNA-seq and WES data.(A) Expression levels of IDO and CTLA-4 in the RIS group and SARC group in mRNA-seq.(B) The anti-tumor immunity score and the proliferation module score of the RIFS group and the RIOS group.(C) The comparison of the anti-tumor immunity score and the proliferation module score between subtypes RIFS vs FS and between RIOS vs OS.(D) Mutation summary of WES data in the RIS and SARC groups.(E) Top 50 mutated genes in RIFS, FS, RIOS and OS subtype groups.
Supplementary Figure S2 from Genomic Profiling of Radiation-Induced Sarcomas Reveals the Immunologic Characteristics and Its Response to Immune Checkpoint Blockade
Authors: Hong Dong-Chun , Yang Jing , Sun Cong , Liu Yuan-Tao , Shen Lu-Jun , Xu Bu-Shu , Que Yi , Xia Xiaojun , Zhang Xing
Published: June 2023

RNA-seq analysis between RIS and RIS groups and some subtypes.(A) Venn plot showing differentially expressed genes (DEG) of FS and OS subtype comparison between RIS and SARC groups.(B) Volcano plot showing up-regulated and down-regulated genes in the RIFS group versus the RIOS group.(C) GO pathway enrichment of mRNA-seq between the RIS group and SARC group, and between the RIFS and RIOS subtypes.(D) Relative abundances of activated immune cells and immunosuppression-related cells in subtypes of RIS and primary sarcomas.
Supplementary Methods S1 from Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases
Authors: Lucero Olivia M. , Lee Ji-Ann , Bowman Jenna , Johnson Kara , Sapparapu Gopal , Thomas John K. , Fan Guang , Chang Bill H. , Thiel-Klare Karina , Eide Christopher A. , Okada Craig , Palazzolo Mike , Lind Evan , Kosaka Yoko , Druker Brian J. , Lydon Nicholas , Bowers Peter M.
Published: June 2023

Supplementary Methods
Supplementary Figure S5 from Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases
Authors: Lucero Olivia M. , Lee Ji-Ann , Bowman Jenna , Johnson Kara , Sapparapu Gopal , Thomas John K. , Fan Guang , Chang Bill H. , Thiel-Klare Karina , Eide Christopher A. , Okada Craig , Palazzolo Mike , Lind Evan , Kosaka Yoko , Druker Brian J. , Lydon Nicholas , Bowers Peter M.
Published: June 2023

Supplementary Figure 5. αVβ monoclonal antibodies induce target T-cell activation, characterized by down modulation of the TCR complex
Supplementary Figure S4 from Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases
Authors: Lucero Olivia M. , Lee Ji-Ann , Bowman Jenna , Johnson Kara , Sapparapu Gopal , Thomas John K. , Fan Guang , Chang Bill H. , Thiel-Klare Karina , Eide Christopher A. , Okada Craig , Palazzolo Mike , Lind Evan , Kosaka Yoko , Druker Brian J. , Lydon Nicholas , Bowers Peter M.
Published: June 2023

Supplementary Figure 4. Target T-cells do not undergo complement dependentcytotoxicity (CDC).
Data from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Authors: Lin Yansong , Qin Shukui , Yang Hui , Shi Feng , Yang Aimin , Han Xingmin , Liu Bin , Li Zhiyong , Ji Qinghai , Tang Lijun , Deng Zhiyong , Ding Yong , Fu Wei , Xie Xianhe , Li Linfa , He Xiaohui , Lv Zhongwei , Ma Qingjie , Shen Zan , Guo Zhuming , Chen Zhendong , Cui Yali , Tan Jian , Gao Zairong , Jing Shanghua , Lu Keyi , Luo Xianyang , Zhang Yuan , Fang Yong , Li Zhendong , Cheng Yizhuang , Lei Shangtong , Luan Sha , Chen Guang , Wang Guihua , Wu Liqing , Liu Lingling
Published: June 2023

AbstractPurpose:
The phase II/III study of donafenib was initiated when there was no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibitor (TKI), showed good efficacy and tolerability in the phase II study. We aimed to further evaluate the antitumor activity and safety of donafenib in Chinese patients with RAIR-DTC.
Patients and Methods:
This multicenter, double-blind, placebo-controlled, phase III study enrolled 191 patients with progressive RAIR–DTC and randomized in a ratio of 2:1 to donafenib (300 mg twice daily, n = 128) or matched placebo (n = 63). An open-label donafenib treatment period was allowed upon disease progression. The primary endpoint was progression-free survival (PFS) assessed by the independent review committee. The second endpoints include objective response rate (ORR), disease control rate (DCR), safety, etc.
Results:
Donafenib demonstrated prolonged median PFS over placebo [12.9 vs. 6.4 months; hazard ratio (HR), 0.39; 95% confidence interval (CI), 0.25–0.61; P < 0.0001] in Chinese patients with RAIR–DTC. Improved ORR (23.3% vs. 1.7%; P = 0.0002) and DCR (93.3% vs. 79.3%; P = 0.0044) were observed in the donafenib group over placebo. For donafenib, the most common grade ≥ 3 treatment-related adverse events (AE) included hypertension (13.3%) and hand–foot syndrome (12.5%), 42.2% underwent dose reduction or interruption, and 6.3% experienced discontinuation.
Conclusions:
Donafenib was well-tolerated and demonstrated clinical benefit in terms of improved PFS, ORR, and DCR in patients with RAIR-DTC. The results suggest that donafenib could be a new treatment option for patients with RAIR-DTC.
Data from Integrative Single-Cell and Bulk Transcriptomes Analyses Identify Intrinsic HNSCC Subtypes with Distinct Prognoses and Therapeutic Vulnerabilities
Authors: Dai Yibin , Wang Ziyu , Xia Yingchao , Li Jin , Wu Yaping , Wang Yanling , Jiang Hongbing , Cheng Jie
Published: June 2023

AbstractPurpose:
Tumor heterogeneity in head and neck squamous cell carcinoma (HNSCC) profoundly compromises patient stratification, personalized treatment planning, and prognostic prediction, which underscores the urgent need for more effective molecular subtyping for this malignancy. Here, we sought to define the intrinsic epithelial subtypes for HNSCC by integrative analyses of single-cell and bulk RNA sequencing datasets from multiple cohorts and assess their molecular features and clinical significance.
Experimental Design:
Malignant epithelial cells were identified from single-cell RNA sequencing (scRNA-seq) datasets and subtyped on the basis of differentially expressed genes. Subtype-specific genomic/epigenetic abnormalities, molecular signaling, genetic regulatory network, immune landscape, and patient survival were characterized. Therapeutic vulnerabilities were further predicted on the basis of drug sensitivity datasets from cell lines, patient-derived xenograft models, and real-world clinical outcomes. Novel signatures for prognostication and therapeutic prediction were developed by machine learning and independently validated.
Results:
Three intrinsic consensus molecular subtypes (iCMS1–3) for HNSCC were proposed from scRNA-seq analyses and recapitulated in 1,325 patients from independent cohorts using bulk-sequencing datasets. iCMS1 was characterized by EGFR amplification/activation, stromal-enriched environment, epithelial-to-mesenchymal transition, worst survival, and sensitivities to EGFR inhibitor. iCMS2 was featured by human papillomavirus–positive oropharyngeal predilection, immune-hot, susceptibilities to anti–PD-1, and best prognosis. Moreover, iCMS3 displayed immune-desert and sensitivities to 5-FU and MEK, STAT3 inhibitors. Three novel, robust signatures derived from iCMS subtype-specific transcriptomics features were developed by machine learning for patient prognostication and cetuximab and anti–PD-1 response predictions.
Conclusions:
These findings reiterate molecular heterogeneity of HNSCC and advantages of scRNA-seq in pinpointing cellular diversities in complex cancer ecosystems. Our HNSCC iCMS regime might facilitate accurate patient stratification and individualized precise treatment.
Data from Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases
Authors: Lucero Olivia M. , Lee Ji-Ann , Bowman Jenna , Johnson Kara , Sapparapu Gopal , Thomas John K. , Fan Guang , Chang Bill H. , Thiel-Klare Karina , Eide Christopher A. , Okada Craig , Palazzolo Mike , Lind Evan , Kosaka Yoko , Druker Brian J. , Lydon Nicholas , Bowers Peter M.
Published: June 2023

AbstractPurpose:
Targeted therapeutics are a goal of medicine. Methods for targeting T-cell lymphoma lack specificity for the malignant cell, leading to elimination of healthy cells. The T-cell receptor (TCR) is designed for antigen recognition. T-cell malignancies expand from a single clone that expresses one of 48 TCR variable beta (Vβ) genes, providing a distinct therapeutic target. We hypothesized that a mAb that is exclusive to a specific Vβ would eliminate the malignant clone while having minimal effects on healthy T cells.
Experimental Design:
We identified a patient with large granular T-cell leukemia and sequenced his circulating T-cell population, 95% of which expressed Vβ13.3. We developed a panel of anti-Vβ13.3 antibodies to test for binding and elimination of the malignant T-cell clone.
Results:
Therapeutic antibody candidates bound the malignant clone with high affinity. Antibodies killed engineered cell lines expressing the patient TCR Vβ13.3 by antibody-dependent cellular cytotoxicity and TCR-mediated activation-induced cell death, and exhibited specific killing of patient malignant T cells in combination with exogenous natural killer cells. EL4 cells expressing the patient's TCR Vβ13.3 were also killed by antibody administration in an in vivo murine model.
Conclusions:
This approach serves as an outline for development of therapeutics that can treat clonal T-cell–based malignancies and potentially other T-cell–mediated diseases.
TABLE 2 from Desmoplastic Reaction Associates with Prognosis and Adjuvant Chemotherapy Response in Colorectal Cancer: A Multicenter Retrospective Study
Authors: Hu Qingru , Wang Yiting , Yao Su , Mao Yun , Liu Liu , Li Zhenhui , Chen Yonghe , Zhang Shenyan , Li Qian , Zhao Yingnan , Fan Xinjuan , Cui Yanfen , Zhao Ke , Liu Zaiyi
Published: June 2023

Univariate and multivariate analyses in primary and validation cohorts
Supplementary Table 5 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b
Authors: Ida Hanae , Shimizu Toshio , Nishino Makoto , Nakamura Yoshiaki , Yazaki Shu , Katsuya Yuki , Sato Jun , Koyama Takafumi , Iwasa Satoru , Sudo Kazuki , Kondo Shunsuke , Yonemori Kan , Shitara Kohei , Shiono Satoshi , Matsuoka Daiko , Yasuda Keisuke , Otake Yohei , Suzuki Takuya , Takase Takao , Takashima Shuya , Yamaguchi Kohei , Semba Taro , Yamamoto Noboru
Published: June 2023

Supplementary Table 5. Summary of Serum Nivolumab Concentrations After the First Dose
Supplementary Table 3 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b
Authors: Ida Hanae , Shimizu Toshio , Nishino Makoto , Nakamura Yoshiaki , Yazaki Shu , Katsuya Yuki , Sato Jun , Koyama Takafumi , Iwasa Satoru , Sudo Kazuki , Kondo Shunsuke , Yonemori Kan , Shitara Kohei , Shiono Satoshi , Matsuoka Daiko , Yasuda Keisuke , Otake Yohei , Suzuki Takuya , Takase Takao , Takashima Shuya , Yamaguchi Kohei , Semba Taro , Yamamoto Noboru
Published: June 2023

Supplementary Table 3. Safety Summary by E7389-LF Dose
Supplementary Table 1 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b
Authors: Ida Hanae , Shimizu Toshio , Nishino Makoto , Nakamura Yoshiaki , Yazaki Shu , Katsuya Yuki , Sato Jun , Koyama Takafumi , Iwasa Satoru , Sudo Kazuki , Kondo Shunsuke , Yonemori Kan , Shitara Kohei , Shiono Satoshi , Matsuoka Daiko , Yasuda Keisuke , Otake Yohei , Suzuki Takuya , Takase Takao , Takashima Shuya , Yamaguchi Kohei , Semba Taro , Yamamoto Noboru
Published: June 2023

Supplementary Table 1. Dose-Limiting Toxicities
Supplementary Methods 1 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b
Authors: Ida Hanae , Shimizu Toshio , Nishino Makoto , Nakamura Yoshiaki , Yazaki Shu , Katsuya Yuki , Sato Jun , Koyama Takafumi , Iwasa Satoru , Sudo Kazuki , Kondo Shunsuke , Yonemori Kan , Shitara Kohei , Shiono Satoshi , Matsuoka Daiko , Yasuda Keisuke , Otake Yohei , Suzuki Takuya , Takase Takao , Takashima Shuya , Yamaguchi Kohei , Semba Taro , Yamamoto Noboru
Published: June 2023

Supplementary Methods
Supplementary Table S5 from Desmoplastic Reaction Associates with Prognosis and Adjuvant Chemotherapy Response in Colorectal Cancer: A Multicenter Retrospective Study
Authors: Hu Qingru , Wang Yiting , Yao Su , Mao Yun , Liu Liu , Li Zhenhui , Chen Yonghe , Zhang Shenyan , Li Qian , Zhao Yingnan , Fan Xinjuan , Cui Yanfen , Zhao Ke , Liu Zaiyi
Published: June 2023

Correlation between DR and TB
Supplementary Figure 4 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b
Authors: Ida Hanae , Shimizu Toshio , Nishino Makoto , Nakamura Yoshiaki , Yazaki Shu , Katsuya Yuki , Sato Jun , Koyama Takafumi , Iwasa Satoru , Sudo Kazuki , Kondo Shunsuke , Yonemori Kan , Shitara Kohei , Shiono Satoshi , Matsuoka Daiko , Yasuda Keisuke , Otake Yohei , Suzuki Takuya , Takase Takao , Takashima Shuya , Yamaguchi Kohei , Semba Taro , Yamamoto Noboru
Published: June 2023

S4. Gene Expression Profiling in Biopsy Tissues
Supplementary Table S4 from Desmoplastic Reaction Associates with Prognosis and Adjuvant Chemotherapy Response in Colorectal Cancer: A Multicenter Retrospective Study
Authors: Hu Qingru , Wang Yiting , Yao Su , Mao Yun , Liu Liu , Li Zhenhui , Chen Yonghe , Zhang Shenyan , Li Qian , Zhao Yingnan , Fan Xinjuan , Cui Yanfen , Zhao Ke , Liu Zaiyi
Published: June 2023

Uni- and multivariate analyses in stage II CRC patients
Supplementary Table S3 from Desmoplastic Reaction Associates with Prognosis and Adjuvant Chemotherapy Response in Colorectal Cancer: A Multicenter Retrospective Study
Authors: Hu Qingru , Wang Yiting , Yao Su , Mao Yun , Liu Liu , Li Zhenhui , Chen Yonghe , Zhang Shenyan , Li Qian , Zhao Yingnan , Fan Xinjuan , Cui Yanfen , Zhao Ke , Liu Zaiyi
Published: June 2023

Uni- and multivariate analyses of DFS
Supplementary Figure 2 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b
Authors: Ida Hanae , Shimizu Toshio , Nishino Makoto , Nakamura Yoshiaki , Yazaki Shu , Katsuya Yuki , Sato Jun , Koyama Takafumi , Iwasa Satoru , Sudo Kazuki , Kondo Shunsuke , Yonemori Kan , Shitara Kohei , Shiono Satoshi , Matsuoka Daiko , Yasuda Keisuke , Otake Yohei , Suzuki Takuya , Takase Takao , Takashima Shuya , Yamaguchi Kohei , Semba Taro , Yamamoto Noboru
Published: June 2023

S2. Linear (A) and Semi-logarithmic (B) Plasma Concentration Profiles of Eribulin After Administration of E7389-LF.
Supplementary Table S2 from Desmoplastic Reaction Associates with Prognosis and Adjuvant Chemotherapy Response in Colorectal Cancer: A Multicenter Retrospective Study
Authors: Hu Qingru , Wang Yiting , Yao Su , Mao Yun , Liu Liu , Li Zhenhui , Chen Yonghe , Zhang Shenyan , Li Qian , Zhao Yingnan , Fan Xinjuan , Cui Yanfen , Zhao Ke , Liu Zaiyi
Published: June 2023

Interobserver Agreement for DR
Supplementary Figure 1 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b
Authors: Ida Hanae , Shimizu Toshio , Nishino Makoto , Nakamura Yoshiaki , Yazaki Shu , Katsuya Yuki , Sato Jun , Koyama Takafumi , Iwasa Satoru , Sudo Kazuki , Kondo Shunsuke , Yonemori Kan , Shitara Kohei , Shiono Satoshi , Matsuoka Daiko , Yasuda Keisuke , Otake Yohei , Suzuki Takuya , Takase Takao , Takashima Shuya , Yamaguchi Kohei , Semba Taro , Yamamoto Noboru
Published: June 2023

S1. Box-and-Whisker Plot of Neutrophil Measurements During Cycle 1 for the (A) Q3W and (B)
Q2W Dosing Groups.
Supplementary Table S1 from Desmoplastic Reaction Associates with Prognosis and Adjuvant Chemotherapy Response in Colorectal Cancer: A Multicenter Retrospective Study
Authors: Hu Qingru , Wang Yiting , Yao Su , Mao Yun , Liu Liu , Li Zhenhui , Chen Yonghe , Zhang Shenyan , Li Qian , Zhao Yingnan , Fan Xinjuan , Cui Yanfen , Zhao Ke , Liu Zaiyi
Published: June 2023

Clinicopathological associations with desmoplastic reaction
Table S9 from Systemic Treatments and Molecular Biomarkers for Perivascular Epithelioid Cell Tumors: A Single-Institution Retrospective Analysis
Authors: Testa Stefano , Bui Nam Q. , Ganjoo Kristen N.
Published: June 2023

Table S9 shows Cox proportional hazard analysis results for clinical progression-free survival from first-line therapy in patients with malignant PEComa.
Supplementary Figure S8 from Desmoplastic Reaction Associates with Prognosis and Adjuvant Chemotherapy Response in Colorectal Cancer: A Multicenter Retrospective Study
Authors: Hu Qingru , Wang Yiting , Yao Su , Mao Yun , Liu Liu , Li Zhenhui , Chen Yonghe , Zhang Shenyan , Li Qian , Zhao Yingnan , Fan Xinjuan , Cui Yanfen , Zhao Ke , Liu Zaiyi
Published: June 2023

Predictive significance of other MSI status on the ACT of stage II CRC
Supplementary Figure S7 from Desmoplastic Reaction Associates with Prognosis and Adjuvant Chemotherapy Response in Colorectal Cancer: A Multicenter Retrospective Study
Authors: Hu Qingru , Wang Yiting , Yao Su , Mao Yun , Liu Liu , Li Zhenhui , Chen Yonghe , Zhang Shenyan , Li Qian , Zhao Yingnan , Fan Xinjuan , Cui Yanfen , Zhao Ke , Liu Zaiyi
Published: June 2023

Predictive significance of other TB on the ACT of stage II CRC
Table S7 from Systemic Treatments and Molecular Biomarkers for Perivascular Epithelioid Cell Tumors: A Single-Institution Retrospective Analysis
Authors: Testa Stefano , Bui Nam Q. , Ganjoo Kristen N.
Published: June 2023

Table S7 shows results of Cox proportional hazard analysis for overall survival in patients with malignant PEComa only.
Supplementary Figure S6 from Desmoplastic Reaction Associates with Prognosis and Adjuvant Chemotherapy Response in Colorectal Cancer: A Multicenter Retrospective Study
Authors: Hu Qingru , Wang Yiting , Yao Su , Mao Yun , Liu Liu , Li Zhenhui , Chen Yonghe , Zhang Shenyan , Li Qian , Zhao Yingnan , Fan Xinjuan , Cui Yanfen , Zhao Ke , Liu Zaiyi
Published: June 2023

Predictive significance of other clinical risk factors on the ACT of stage II CRC
Supplementary Figure S5 from Desmoplastic Reaction Associates with Prognosis and Adjuvant Chemotherapy Response in Colorectal Cancer: A Multicenter Retrospective Study
Authors: Hu Qingru , Wang Yiting , Yao Su , Mao Yun , Liu Liu , Li Zhenhui , Chen Yonghe , Zhang Shenyan , Li Qian , Zhao Yingnan , Fan Xinjuan , Cui Yanfen , Zhao Ke , Liu Zaiyi
Published: June 2023

Prognostic significance of DR categorization in different subgroups of CRC patients
Table S5 from Systemic Treatments and Molecular Biomarkers for Perivascular Epithelioid Cell Tumors: A Single-Institution Retrospective Analysis
Authors: Testa Stefano , Bui Nam Q. , Ganjoo Kristen N.
Published: June 2023

Table S5 shows DCR and ORR based on biomarker status and primary tumor site, considering all treatment episodes, and mTOR inhibitors only.
Table S4 from Systemic Treatments and Molecular Biomarkers for Perivascular Epithelioid Cell Tumors: A Single-Institution Retrospective Analysis
Authors: Testa Stefano , Bui Nam Q. , Ganjoo Kristen N.
Published: June 2023

Table S4 shows the best disease control rate (DCR) and overall response rate (ORR) for mTOR inhibitors compared to other treatments based on histotype.
Supplementary Figure S4 from Desmoplastic Reaction Associates with Prognosis and Adjuvant Chemotherapy Response in Colorectal Cancer: A Multicenter Retrospective Study
Authors: Hu Qingru , Wang Yiting , Yao Su , Mao Yun , Liu Liu , Li Zhenhui , Chen Yonghe , Zhang Shenyan , Li Qian , Zhao Yingnan , Fan Xinjuan , Cui Yanfen , Zhao Ke , Liu Zaiyi
Published: June 2023

Prognostic significance of DR categorization in each TNM stages of CRC patients
Supplementary Figure S2 from Desmoplastic Reaction Associates with Prognosis and Adjuvant Chemotherapy Response in Colorectal Cancer: A Multicenter Retrospective Study
Authors: Hu Qingru , Wang Yiting , Yao Su , Mao Yun , Liu Liu , Li Zhenhui , Chen Yonghe , Zhang Shenyan , Li Qian , Zhao Yingnan , Fan Xinjuan , Cui Yanfen , Zhao Ke , Liu Zaiyi
Published: June 2023

Histological features of the desmoplastic reaction
Table S11 from Systemic Treatments and Molecular Biomarkers for Perivascular Epithelioid Cell Tumors: A Single-Institution Retrospective Analysis
Authors: Testa Stefano , Bui Nam Q. , Ganjoo Kristen N.
Published: June 2023

Table S11 shows median clinical PFS for all treatment episodes in months, as well as 5-year clinical PFS rate for all treatment episodes in the whole cohort.
FIGURE 4 from Desmoplastic Reaction Associates with Prognosis and Adjuvant Chemotherapy Response in Colorectal Cancer: A Multicenter Retrospective Study
Authors: Hu Qingru , Wang Yiting , Yao Su , Mao Yun , Liu Liu , Li Zhenhui , Chen Yonghe , Zhang Shenyan , Li Qian , Zhao Yingnan , Fan Xinjuan , Cui Yanfen , Zhao Ke , Liu Zaiyi
Published: June 2023

Correlation between DR and TILs, tumor stroma ratio. A, The workflow of TILs within stroma and TSR quantification. B and C, The correlation between DR and TILS within stroma. D and E, The correlation between DR and TSR. DR, desmoplastic reaction; TILs, tumor-infiltrating lymphocytes; TSR, tumor stroma ratio (Note: The P values of multiple comparisons in B and D were adjusted with Benjamini–Hochberg correction.).
Table S10 from Systemic Treatments and Molecular Biomarkers for Perivascular Epithelioid Cell Tumors: A Single-Institution Retrospective Analysis
Authors: Testa Stefano , Bui Nam Q. , Ganjoo Kristen N.
Published: June 2023

Table S10 shows median clinical PFS from first-line therapy in months, as well as 5-year clinical PFS rate from first-line therapy in patients with malignant PEComa.
FIGURE 2 from Desmoplastic Reaction Associates with Prognosis and Adjuvant Chemotherapy Response in Colorectal Cancer: A Multicenter Retrospective Study
Authors: Hu Qingru , Wang Yiting , Yao Su , Mao Yun , Liu Liu , Li Zhenhui , Chen Yonghe , Zhang Shenyan , Li Qian , Zhao Yingnan , Fan Xinjuan , Cui Yanfen , Zhao Ke , Liu Zaiyi
Published: June 2023

Prognostic significance of DR categorization for patients with colorectal cancer in the two cohorts. A, Primary cohort. B, Validation cohort. HR, hazard ratio; DR, desmoplastic reaction.
Figure S9 from Systemic Treatments and Molecular Biomarkers for Perivascular Epithelioid Cell Tumors: A Single-Institution Retrospective Analysis
Authors: Testa Stefano , Bui Nam Q. , Ganjoo Kristen N.
Published: June 2023

Figure S9 shows Kaplan-Meier curves for combined clinical PFS in patients with malignant PEComas. Specifically, figure shows effects on combined clinical PFS of TFE3 positivity, treatment type, and TP53 and TSC1/TSC2 mutational status.
FIGURE 1 from Desmoplastic Reaction Associates with Prognosis and Adjuvant Chemotherapy Response in Colorectal Cancer: A Multicenter Retrospective Study
Authors: Hu Qingru , Wang Yiting , Yao Su , Mao Yun , Liu Liu , Li Zhenhui , Chen Yonghe , Zhang Shenyan , Li Qian , Zhao Yingnan , Fan Xinjuan , Cui Yanfen , Zhao Ke , Liu Zaiyi
Published: June 2023

Study workflow. A, H&E-stained WSIs were used to assess the DR. B, Categorization of DR, DR in the reactive fibrous area at the extramural leading edge of the primary tumor were classified into three categories based on the presence or absence of myxoid stroma or keloid-like collagen. C, Cohort composition, primary cohort (from GDPH and SYSU6), validation cohort (from YNCH, SXCH, and CQMU1). D, The prognostic value of DR categorization was evaluated by Kaplan–Meier curves. CRC, colorectal cancer; DR, desmoplastic reaction; H&E, hematoxylin and eosin, WSIs, whole-slide images.
Figure S4 from Systemic Treatments and Molecular Biomarkers for Perivascular Epithelioid Cell Tumors: A Single-Institution Retrospective Analysis
Authors: Testa Stefano , Bui Nam Q. , Ganjoo Kristen N.
Published: June 2023

Figure S4 shows Kaplan-Meier curves for Overall Survival in patients with PEComas and effect of TSC1/TSC2 and TP53 mutation on Overall Survival.
Data from Desmoplastic Reaction Associates with Prognosis and Adjuvant Chemotherapy Response in Colorectal Cancer: A Multicenter Retrospective Study
Authors: Hu Qingru , Wang Yiting , Yao Su , Mao Yun , Liu Liu , Li Zhenhui , Chen Yonghe , Zhang Shenyan , Li Qian , Zhao Yingnan , Fan Xinjuan , Cui Yanfen , Zhao Ke , Liu Zaiyi
Published: June 2023

Desmoplastic reaction (DR) is one of many tumor–host interactions and is associated with the overall survival (OS) of patients with colorectal cancer. However, the clinical significance of DR requires further study in large multicenter cohorts and its predictive value in adjuvant chemotherapy (ACT) response remains unclear. Here, a total of 2,225 patients with colorectal cancer from five independent institutions were divided into primary (N = 1,012 from two centers) and validation (N = 1,213 from three centers) cohorts. DR was classified as immature, middle, or mature depending on the presence of myxoid stroma and hyalinized collagen bundles at the invasive front of the primary tumor. OS among different subgroups were compared, and the correlations of DR type with tumor-infiltrating lymphocytes (TILs) within stroma, tumor stroma ratio (TSR), and Stroma AReactive Invasion Front Areas (SARIFA) were also analyzed. In the primary cohort, patients with mature DR had the highest 5-year survival rate. These findings were confirmed in validation cohort. In addition, for stage II colorectal cancer, patients classified as non-mature DR would benefit from ACT compared with surgery alone. Furthermore, immature and middle DR were more associated with high TSR, less distribution of TILs within stroma and positive SARIFA compared with mature. Taken together, these data suggest that DR is a robust-independent prognostic factor for patients with colorectal cancer. For patients with stage II colorectal cancer, non-mature DR could be a potential marker for recognizing high-risk patients who may benefit from ACT.
Significance:
DR has the potential to identify patients with high-risk colorectal cancer and predict the efficacy of adjuvant chemotherapy in patients with stage II colorectal cancer. Our findings support reporting DR types as additional pathologic parameters in clinical practice for more precise risk stratification.
Data from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b
Authors: Ida Hanae , Shimizu Toshio , Nishino Makoto , Nakamura Yoshiaki , Yazaki Shu , Katsuya Yuki , Sato Jun , Koyama Takafumi , Iwasa Satoru , Sudo Kazuki , Kondo Shunsuke , Yonemori Kan , Shitara Kohei , Shiono Satoshi , Matsuoka Daiko , Yasuda Keisuke , Otake Yohei , Suzuki Takuya , Takase Takao , Takashima Shuya , Yamaguchi Kohei , Semba Taro , Yamamoto Noboru
Published: June 2023

Abstract
Purpose: To determine a recommended dose of liposomal eribulin (E7389-LF) in combination with nivolumab in patients with advanced solid tumors, and to evaluate the safety, efficacy, pharmacokinetics, and biomarker impact of this regimen.

Patients and Methods: Japanese patients with advanced, nonresectable, or recurrent solid tumors and no existing alternative standard/effective therapy (except nivolumab monotherapy) were assigned to either E7389-LF 1.7 mg/m2 plus nivolumab 360 mg every 3 weeks (Q3W), E7389-LF 2.1 mg/m2 plus nivolumab 360 mg Q3W, E7389-LF 1.1 mg/m2 plus nivolumab 240 mg every 2 weeks (Q2W), or E7389-LF 1.4 mg/m2 plus nivolumab 240 mg Q2W. Primary objectives were to evaluate the safety/tolerability of each dose cohort and to determine the recommended phase 2 dose (RP2D). Secondary/exploratory objectives, including safety (dose-limiting toxicities [DLTs] and adverse events [AEs]), pharmacokinetics, efficacy (including objective response rate [ORR]), and biomarker results were used in determining the RP2D.

Results:Twenty-five patients were enrolled to treatment (E7389-LF 1.7 mg/mg2 Q3W [n=6], E7389-LF 2.1 mg/m2 Q3W [n=6], E7389-LF 1.1 mg/m2 Q2W [n=7], E7389-LF 1.4 mg/m2 Q2W [n=6]). Twenty-four patients were evaluated for DLTs, of whom 3 had DLTs (1 at E7389-LF 1.7 mg/m2 Q3W, 1 at 1.1 mg/m2 Q2W, and 1 at 1.4 mg/m2 Q2W). All patients had ≥1 treatment related treatment-emergent AE (TEAE); 68.0% had ≥1 grade 3-4 treatment-related TEAE. Changes in vasculature and interferon-related biomarkers were seen in each cohort. The overall ORR was 16%.

Conclusions: E7389-LF plus nivolumab was tolerable overall; the recommended dose for future studies was 2.1 mg/m2 plus nivolumab 360 mg Q3W.